Townsquare Capital LLC Purchases Shares of 966 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Townsquare Capital LLC acquired a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 966 shares of the biopharmaceutical company’s stock, valued at approximately $227,000.

A number of other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. grew its stake in shares of Alnylam Pharmaceuticals by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 12,733,399 shares of the biopharmaceutical company’s stock worth $2,996,296,000 after buying an additional 98,303 shares in the last quarter. Regeneron Pharmaceuticals Inc. bought a new stake in Alnylam Pharmaceuticals during the fourth quarter worth approximately $1,045,822,000. Norges Bank purchased a new stake in Alnylam Pharmaceuticals during the fourth quarter valued at approximately $577,941,000. Geode Capital Management LLC lifted its stake in shares of Alnylam Pharmaceuticals by 2.8% in the 4th quarter. Geode Capital Management LLC now owns 2,206,800 shares of the biopharmaceutical company’s stock valued at $518,367,000 after purchasing an additional 59,597 shares during the last quarter. Finally, American Century Companies Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 0.7% in the 4th quarter. American Century Companies Inc. now owns 1,604,024 shares of the biopharmaceutical company’s stock worth $377,443,000 after purchasing an additional 11,291 shares during the period. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Insider Activity

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 1,213 shares of the firm’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $309,521.21. Following the transaction, the chief executive officer now owns 81,526 shares of the company’s stock, valued at $20,802,989.42. This trade represents a 1.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Phillip A. Sharp sold 11,250 shares of the business’s stock in a transaction that occurred on Thursday, January 23rd. The shares were sold at an average price of $275.00, for a total value of $3,093,750.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 71,234 shares of company stock worth $19,958,097. 1.50% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

ALNY has been the subject of a number of recent analyst reports. William Blair reaffirmed an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Friday, March 21st. Redburn Atlantic initiated coverage on Alnylam Pharmaceuticals in a research report on Monday, March 31st. They set a “buy” rating and a $353.00 target price for the company. Morgan Stanley reduced their price target on Alnylam Pharmaceuticals from $284.00 to $268.00 and set an “equal weight” rating on the stock in a report on Friday, April 11th. Wells Fargo & Company boosted their price objective on Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the company an “equal weight” rating in a report on Friday, March 21st. Finally, HC Wainwright reiterated a “buy” rating and issued a $500.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday, April 2nd. One analyst has rated the stock with a sell rating, four have issued a hold rating and twenty-two have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $315.58.

Alnylam Pharmaceuticals Price Performance

Alnylam Pharmaceuticals stock opened at $236.75 on Wednesday. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. The firm has a market capitalization of $30.80 billion, a P/E ratio of -109.10 and a beta of 0.30. The firm has a fifty day moving average of $247.91 and a 200-day moving average of $256.50. Alnylam Pharmaceuticals, Inc. has a 52-week low of $141.98 and a 52-week high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03). As a group, analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.